In a multicenter trial involving patients with acute hypoxemic respiratory failure, 28-day mortality with high-flow oxygen was not significantly different from that with standard oxygen.
Author: Jean-Pierre Frat, Jean-Pierre Quenot, Christophe Guitton, Rémi Coudroy, Arnaud Gacouin, Julio Badie, Alexandre Demoule, Damien Contou, Guillaume Carteaux, Stephan Ehrmann, Fabien Jarousseau, Nicholas Sedillot, Jean-Philippe Rigaud, Jean Reignier, François Beloncle, Anne-Florence Dureau, Alexis Ferré, Cédric Daubin, Anna Bourreau, Agathe Delbove, Gaël Pradel, Abdelhamid Fatah, Gwenhael Colin, Guillaume Deniel, Olivier Lamouret, Béatrice La Combe, Gwénaël Prat, Louis-Marie Galerneau, Gaël Bourdin, Gautier Julien, Anaïs Curtiaud, Mélanie Saint-Léger, Emanuele Turbil, Faustine Reynaud, Louis Chamblet, Stéphanie Ragot, Arnaud W. Thille, the SOHO Trial Group and the REVA Network*
Posted: June 4, 2026, 12:00 am
Acute hypoxemic respiratory failure remains one of the most common conditions encountered in the intensive care unit (ICU).1 During the past decade, high-flow nasal oxygen has moved from physiological curiosity to frontline therapy.2 Early enthusiasm followed the publication of the results of the 2015 FLORALI trial,
Author: Ary Serpa Neto
Posted: June 4, 2026, 12:00 am
IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1
Author: Thomas Dörner
Posted: June 2, 2026, 12:00 am
The story of the pulse oximeter demonstrates that sometimes consideration of race is critical to diagnosis and treatment — as came starkly into light during the Covid-19 pandemic.
Posted: May 28, 2026, 12:00 am
Pulmonary embolism is the third leading cardiovascular cause of complications and death after myocardial infarction and stroke, with a rising incidence globally.1 The approach to management of acute pulmonary embolism as a condition to be treated nonsurgically with systemic heparin anticoagulation was established more than 60 years ago.
Author: Alex C. Spyropoulos, Suresh Vedantham
Posted: May 28, 2026, 12:00 am
Bronchoscopy in a 77-year-old man with suspected lung cancer showed black patches on the bronchial mucosa. Biopsy revealed ciliated epithelium with subepithelial accumulation of macrophages containing black pigment.
Author: Fredrik Eika, Torpiki Abdul Abdulhaq
Posted: May 28, 2026, 12:00 am
In patients with pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis led to a lower risk of a composite of major adverse outcomes than anticoagulation alone.
Author: Kenneth Rosenfield, Frederikus A. Klok, Gregory Piazza, Andrew S.P. Sharp, Fionnuala Ní Áinle, Michael R. Jaff, Stefano Barco, Samuel Z. Goldhaber, Nils Kucher, Irene M. Lang, Irene Schmidtmann, Keith M. Sterling, Aleksander Araszkiewicz, Vishal Arora, Rafael Cires-Drouet, John Coghlan, Lukas Hobohm, Wulf D. Ito, Kurt Jacobson, Christoph Kaiser, Grzegorz Kopec, Kristin Marx, Samuel McElwee, Nicolas Meneveau, Peter Monteleone, Jose M. Montero-Cabezas, Christoph B. Olivier, John Park, Marek Roik, Rahul Sakhuja, Andi Tego, Markus Theurl, Gautam Visveswaran, Jan Albert Vos, Michael N. Young, Federico M. Asch, Stavros V. Konstantinides, the HI-PEITHO Investigators*
Posted: May 28, 2026, 12:00 am
Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood.
Author: Jason L. Sperry, Francis X. Guyette, Bryan A. Cotton, James F. Luther, Richard B. Utarnachitt, Matthew E. Kutcher, Brian J. Daley, Allan B. Peetz, Mayur B. Patel, Michael D. Goodman, Jeffrey A. Claridge, Nimitt Patel, Brian G. Harbrecht, Zain G. Hashmi, Ryan Zarychanski, Matthew D. Neal, Mark H. Yazer, Christian Martin-Gill, Laura E. Vincent, Ashley M. Harner, David E. Meyer, Andrew J. Latimer, Bryce R. Robinson, Catherine L. McKnight, William R. Hinckley, Keith R. Miller, Jan O. Jansen, Douglas Martin, Erin E. Fox, Bedda L. Rosario-Rivera, Stephen R. Wisniewski, the TOWAR Study Group*
Posted: May 18, 2026, 12:00 am
Azithromycin did not lead to a greater reduction in symptom severity than placebo among preschool children presenting to the emergency department with wheezing, regardless of whether they tested positive for pathogenic bacteria.
Author: Kurt R. Denninghoff, T. Charles Casper, Joseph J. Zorc, Richard M. Ruddy, Sarah Satola, Wendi-Jo Wendt, Claudia R. Morris, Melissa M. Tavarez, Matthew J. Lipshaw, Maria Y. Kwok, Jo-Ann O. Nesiama, Kyle A. Nelson, Michael Webb, Fernando D. Martinez, the PECARN AZ-SWED Trial Study Group*
Posted: May 18, 2026, 12:00 am
Among patients with idiopathic pulmonary fibrosis, inhaled treprostinil led to a smaller decline in forced vital capacity than placebo over 52 weeks. Cough and drug discontinuation were more common with treprostinil.
Author: Steven D. Nathan, Peter Smith, Chunqin Deng, Christopher S. King, Maria De Salvo, S. Samuel Weigt, Sahil Pandya, Debabrata Bandyopadhyay, Joseph A. Lasky, Rachana Krishna, Nathan Hambly, Murali Ramaswamy, Jad Kebbe, Neil Ettinger, Jamie Gao, Youlan Rao, Natalie Breytenbach, Leigh Peterson, Heidi Bell, Juergen Behr, Vincent Cottin, Kevin R. Flaherty, the TETON-1 Trial Investigators*
Posted: May 18, 2026, 12:00 am